The overall goal of the proposal is to develop an automated data acquisition system for non-invasive quantitative cancer detection, screening, and monitoring, based on highly sensitive low volume real time PCR technique and capillary electrophoresis, apply this system for quantitative analysis of the telomerase activity and gene expression in single cancer cells, and to validate this system on clinical specimens using exfoliated cancer cells in voided urine of prostate cancer patients. Phase I of the project aims at building the bench-top prototype of the detection system and determination of the limits of sensitivity of the proposed instrument for quantitative measurement of telomerase activity and hTERT mRNA expression in comparison with the sensitivity of one of the best commercial real-time PCR instruments, OpticonTM, MJ Research, available at SUNY core facility, and/or ABI PRISM TM7700, PE Applied Biosystems. In Phase II we will develop an automated pilot prototype of the data acquisition system, validate the instrument using exfoliated cancer cells in voided urine specimens of prostate cancer patients, and develop optimal protocols for clinical sample preparation and analysis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Technology Transfer (STTR) Grants - Phase II (R42)
Project #
5R42CA106193-03
Application #
7126413
Study Section
Special Emphasis Panel (ZCA1-SRRB-C (O1))
Program Officer
Rasooly, Avraham
Project Start
2004-09-01
Project End
2008-08-31
Budget Start
2006-09-01
Budget End
2007-08-31
Support Year
3
Fiscal Year
2006
Total Cost
$371,556
Indirect Cost
Name
Biophotonics Corporation
Department
Type
DUNS #
119738131
City
Stony Brook
State
NY
Country
United States
Zip Code
11790